Gefitinib has been described able to decrease synthesis of matrix metalloproteinase of colon cancer cells, and more recently miRNA-124 showed to indirect inhibit MMP9 via the transcription factor Signal transducer and activator of transcription 3 (STAT3) modulation [101,102]. The gene discussed is STAT3; the disease is colonic neoplasm.